INT9500

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1989
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 26
Total Number 26
Disease Relevance 6.89
Pain Relevance 3.91

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Ceacam1) cell adhesion (Ceacam1) plasma membrane (Ceacam1)
Anatomy Link Frequency
spinal 2
urine 1
Ceacam1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Pain 40 99.92 Very High Very High Very High
antagonist 20 99.32 Very High Very High Very High
imagery 9 98.44 Very High Very High Very High
adenocard 54 97.62 Very High Very High Very High
Clonidine 2 93.68 High High
Glutamate 8 93.64 High High
opioid receptor 4 93.20 High High
backache 1 91.88 High High
Enkephalin 8 86.28 High High
vagus nerve 4 86.00 High High
Disease Link Frequency Relevance Heat
Hypercalcemia 43 100.00 Very High Very High Very High
Pain 15 99.92 Very High Very High Very High
Osteogenesis Imperfecta 25 99.66 Very High Very High Very High
Hypocalcemia 1 98.84 Very High Very High Very High
Familial Hypophosphatemia 2 98.68 Very High Very High Very High
Rickets 5 97.96 Very High Very High Very High
Stress 21 97.86 Very High Very High Very High
Body Weight 5 95.88 Very High Very High Very High
Compression Fractures 4 94.04 High High
Low Back Pain 1 91.88 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Explorative post hoc analyses revealed that ibandronate patients with strongly suppressed bone-turnover markers (> or = 30% and > or = 50% mean reduction of serum osteocalcin and urinary C-terminal telopeptides) developed significantly less bone morbidity.
Negative_regulation (reduction) of osteocalcin
1) Confidence 0.58 Published 2002 Journal J. Clin. Oncol. Section Body Doc Link 11981007 Disease Relevance 0.06 Pain Relevance 0
The patient had good renal function, a parathormone independent hyperphosphaturia, normal 25-OH cholecalciferol, increased urinary hydroxyproline, decreased osteocalcin, reduced bone density and a bone biopsy revealing osteomalacia.
Negative_regulation (decreased) of osteocalcin associated with familial hypophosphatemia and rickets
2) Confidence 0.42 Published 1995 Journal Rev Med Chil Section Abstract Doc Link 7569451 Disease Relevance 1.05 Pain Relevance 0.09
Serum osteocalcin (BGP) and urinary HO-proline/creatinine (HOP/Cr) values were reduced in the same group.
Negative_regulation (reduced) of Serum osteocalcin
3) Confidence 0.41 Published 1992 Journal Bone Miner Section Abstract Doc Link 1422322 Disease Relevance 0.17 Pain Relevance 0.09
The possible contribution of ATP hydrolysis to the degradation of ATP in isolated spinal roots was studied by means of known inhibitors of ecto-nucleotidases [13].
Negative_regulation (inhibitors) of ecto-nucleotidases in spinal
4) Confidence 0.35 Published 2006 Journal Purinergic Signal Section Body Doc Link PMC2096649 Disease Relevance 0.18 Pain Relevance 0.06
The importance of ecto-nucleotidases for the recovery period was determined by exposure of isolated spinal roots to high concentrations of ATP and by use of inhibitors of ecto-nucleotidases.
Negative_regulation (inhibitors) of ecto-nucleotidases in spinal
5) Confidence 0.35 Published 2006 Journal Purinergic Signal Section Abstract Doc Link PMC2096649 Disease Relevance 0.14 Pain Relevance 0.14
Therapy was associated with a reduction in urine N-telopeptides and a trend toward a reduction in serum osteocalcin, but no change occurred in bone-specific alkaline phosphatase.
Negative_regulation (reduction) of osteocalcin in urine
6) Confidence 0.35 Published 2004 Journal Urology Section Body Doc Link 15134984 Disease Relevance 0.11 Pain Relevance 0
Figure 6Modulation of ATP degradation by ecto-ATPase inhibitors.
Negative_regulation (inhibitors) of ecto-ATPase
7) Confidence 0.30 Published 2006 Journal Purinergic Signal Section Body Doc Link PMC2096649 Disease Relevance 0 Pain Relevance 0
Also, ARL 67156 is often used as a blocker of ecto-ATPases [25].
Negative_regulation (blocker) of ecto-ATPases
8) Confidence 0.26 Published 2006 Journal Purinergic Signal Section Body Doc Link PMC2096649 Disease Relevance 0.07 Pain Relevance 0.04
The effect of DPCPX and ZM241385 was reversed, whereas the action of P2 receptor antagonists was potentiated by the selective ecto-ATPase inhibitor 6-N,N-diethyl-D-beta,gamma-dibromomethyleneATP (ARL67156, 50 microM).
Negative_regulation (inhibitor) of ecto-ATPase associated with antagonist
9) Confidence 0.25 Published 2007 Journal Neuroscience Section Abstract Doc Link 17850981 Disease Relevance 0.07 Pain Relevance 0.76
An energy availability between 20–30 kcal/kgFFM/d has also been found to impair bone formation due to a sharp decline in the osteocalcin available for bone matrix mineralization [11], as well as possible estrogen-independent mechanisms that include a disruption, also induced by low energy availability, of metabolic hormones such as triiodothyronine (T3) and insulin-like growth factor (IGF)-I.
Negative_regulation (decline) of osteocalcin
10) Confidence 0.22 Published 2008 Journal J Int Soc Sports Nutr Section Body Doc Link PMC2235827 Disease Relevance 0.37 Pain Relevance 0
Mean relative reduction of serum osteocalcin for daily and intermittent ibandronate was 35% and 32%, respectively, after 6 months, and 42% and 38%, respectively, after 1 year.
Negative_regulation (reduction) of osteocalcin
11) Confidence 0.14 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661644 Disease Relevance 0.16 Pain Relevance 0
The selective ecto-ATPase inhibitor, ARL-67156 (100, 200 microM) and suramin (100, 200 microM), an ecto-nucleotidase inhibitor as well as a P2 receptor antagonist, produced an increase in baseline and distension-induced discharge.
Negative_regulation (inhibitor) of ecto-nucleotidase associated with antagonist
12) Confidence 0.11 Published 2004 Journal Neuropharmacology Section Abstract Doc Link 15555643 Disease Relevance 0 Pain Relevance 0.39
As a result, we conclude that AA given before anaesthesia achieved by etomidate is not sufficient for the prevention of surgical stress response and that AA induction before anaesthesia should be preferred, particularly for the prevention of decrease in osteocalcin levels.
Negative_regulation (decrease) of osteocalcin associated with stress
13) Confidence 0.11 Published 2004 Journal Int. J. Clin. Pract. Section Abstract Doc Link 15587771 Disease Relevance 0.17 Pain Relevance 0.14
The parameters investigated showed a significant reduction of osteocalcin in the ipriflavone group that indicates a modulation on bone turnover.
Negative_regulation (reduction) of osteocalcin
14) Confidence 0.11 Published 1989 Journal Drugs Exp Clin Res Section Abstract Doc Link 2661184 Disease Relevance 0.44 Pain Relevance 0.17
Serum osteocalcin and cross-laps levels were significantly reduced.
Negative_regulation (reduced) of osteocalcin
15) Confidence 0.11 Published 2010 Journal International Journal of Ayurveda Research Section Body Doc Link PMC2924974 Disease Relevance 0.53 Pain Relevance 0.03
The selective ecto-ATPase inhibitor, ARL-67156 (100, 200 microM) and suramin (100, 200 microM), an ecto-nucleotidase inhibitor as well as a P2 receptor antagonist, produced an increase in baseline and distension-induced discharge.
Negative_regulation (inhibitor) of ecto-ATPase associated with antagonist
16) Confidence 0.10 Published 2004 Journal Neuropharmacology Section Abstract Doc Link 15555643 Disease Relevance 0 Pain Relevance 0.40
Daily ibandronate reduced markers of bone resorption (urinary CTX and urinary NTX) significantly to a steady state level of approximately 65%–70% (Delmas, Recker, et al 2004), and serum osteocalcin to a level of approximately 40%.
Negative_regulation (reduced) of osteocalcin associated with hypercalcemia
17) Confidence 0.10 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661644 Disease Relevance 0.29 Pain Relevance 0
A significant decrease in bone turnover markers (osteocalcin, C-terminal telopeptide of type 1 collagen and N-terminal propeptide of type 1 procollagen) was also observed at 6 and 24 months in lasofoxifene treatment groups with respect to placebo.
Negative_regulation (decrease) of osteocalcin
18) Confidence 0.10 Published 2010 Journal Clin Interv Aging Section Body Doc Link PMC2817938 Disease Relevance 0.51 Pain Relevance 0.07
Whereas, patients in Group II had higher levels of cortisol than the control group at sixth hour, which were in normal limits, and there was no decrease in osteocalcin concentration.
Neg (no) Negative_regulation (decrease) of osteocalcin
19) Confidence 0.08 Published 2004 Journal Int. J. Clin. Pract. Section Abstract Doc Link 15587771 Disease Relevance 0.37 Pain Relevance 0.19
ATP (60 nmol), added to the tissues, was readily decomposed to ADP, AMP and adenosine measured by HPLC combined with ultraviolet light detection, and the kinetic parameters of the enzymes responsible for inactivation of ATP (ectoATPase and ecto5'-nucleotidase) were also determined (Km=264+/-2.7 and 334+/-165 microM and vmax=6.7+/-1.1 and 2.54+/-0.24 nmol/min per preparation (n=3) for ectoATPase and ecto5'-nucleotidase respectively).
Negative_regulation (inactivation) of ectoATPase associated with adenocard
20) Confidence 0.06 Published 1999 Journal J. Endocrinol. Section Abstract Doc Link 10076181 Disease Relevance 0 Pain Relevance 0.16

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox